Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
复制标题
DOI：
10.3324/haematol.2022.281242
复制
发表时间：
2023-01-01
期刊：
影响因子：
10.1
通讯作者：
Herrera, Alex F.
中科院分区：
文献类型：
--
作者：
Zurko, Joanna;Ramdial, Jeremy;Shadman, Mazyar;Ahmed, Sairah;Szabo, Aniko;Iovino, Lorenzo;Tomas, Ana Alarcon;Sauter, Craig;Perales, Miguel-Angel;Shah, Nirav. N.;Acharya, Utkarsh H.;Jacobson, Caron;Soiffer, Robert J.;Wang, Trent;Komanduri, Krishna, V;Jaglowski, Samantha;Kittai, Adam S.;Denlinger, Nathan;Iqbal, Madiha;Kharfan-Dabaja, Mohamed A.;Ayala, Ernesto;Chavez, Julio;Jain, Michael;Locke, Frederick L.;Samara, Yazeed;Budde, Lihua E.;Mei, Matthew G.;Della Pia, Alexandra;Feldman, Tatyana;Ahmed, Nausheen;Jacobs, Ryan;Ghosh, Nilanjan;Dholaria, Bhagirathbhai;Oluwole, Olalekan O.;Hess, Brian;Hassan, Ayesha;Kenkre, Vaishalee P.;Reagan, Patrick;Awan, Farrukh;Nieto, Yago;Hamadani, Mehdi;Herrera, Alex F.
异基因造血细胞移植(AllHCT)可以挽救嵌合抗原受体T细胞治疗(CAR T)后治疗失败的大B细胞淋巴瘤(LBCL)患者。尽管如此，关于接受CAR T后异体HCT的疗效和毒性的数据有限。我们报告了一项多中心的回顾性研究，评估CAR失败后LBCL患者接受allHCT的安全性、毒性和结局。88名复发的难治性LBCL患者在抗CD19 Car T失败后接受了异基因HCT治疗。CAR T输注和异基因HCT之间的治疗路线的中位数为1(范围0-7)。77%(n=68)采用低强度预适应，最常见的移植物来源是外周血(86%，n=76)。最常见的供者类型是匹配的非亲缘关系供者(39%)，其次是单倍体相合的(30%)和匹配的亲缘供者(26%)。幸存者的中位随访期为15个月(范围1-72个月)。一年总生存率、无进展生存率和移植物抗宿主病无复发生存率分别为59%、45%和39%。1年无复发死亡率和进展/复发分别为22%和33%。在多变量分析中，CAR-T和allHCT之间的两行介入治疗和在allHCT时的完全反应与较好的结果相关。总而言之，CAR T失败后的allHCT可以为部分患者提供持久的缓解。
Allogeneic hematopoietic cell transplantation (alloHCT) can potentially salvage large B-cell lymphoma (LBCL) patients experiencing treatment failure after chimeric antigen receptor T-cell therapy (CAR T). Nonetheless, data on the efficacy and toxicities of alloHCT after receipt of CAR T are limited. We report a multicenter retrospective study assessing the safety, toxicities, and outcomes of alloHCT in LBCL patients following CAR T failure. Eighty-eight patients with relapsed, refractory LBCL received an alloHCT following anti-CD19 CAR T failure. The median number of lines of therapy between CAR T infusion and alloHCT was one (range, 0-7). Low intensity conditioning was used in 77% (n=68) and peripheral blood was the most common graft source (86%, n=76). The most common donor types were matched unrelated donor (39%), followed by haploidentical (30%) and matched related donor (26%). Median follow-up of survivors was 15 months (range, 1-72). One-year overall survival, progression-free survival, and graft-versus-host disease-free relapse-free survival were 59%, 45%, and 39% respectively. One-year non-relapse mortality and progression/relapse were 22% and 33% respectively. On multivariate analysis, <2 lines of intervening therapy between CAR T and alloHCT and complete response at time of alloHCT were associated with better outcomes. In conclusion, alloHCT after CAR T failure can provide durable remissions in a subset of patients.
登录
查看更多内容
影响因子：
7.5
作者：
Hamadani M;Gopal AK;Pasquini M;Kim S;Qiu X;Ahmed S;Lazaryan A;Bhatt VR;Daly A;Lulla P;Ciurea S;Gauthier J;Agrawal V;Grover NS;Lekakis L;Modi D;Dahi PB;Herr MM;Johnson PC;Hashmi H;Hematti P;Locke FL
通讯作者：
Locke FL
DOI：
10.1056/nejmoa1707447
发表时间：
2017-12-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Neelapu SS;Locke FL;Bartlett NL;Lekakis LJ;Miklos DB;Jacobson CA;Braunschweig I;Oluwole OO;Siddiqi T;Lin Y;Timmerman JM;Stiff PJ;Friedberg JW;Flinn IW;Goy A;Hill BT;Smith MR;Deol A;Farooq U;McSweeney P;Munoz J;Avivi I;Castro JE;Westin JR;Chavez JC;Ghobadi A;Komanduri KV;Levy R;Jacobsen ED;Witzig TE;Reagan P;Bot A;Rossi J;Navale L;Jiang Y;Aycock J;Elias M;Chang D;Wiezorek J;Go WY
通讯作者：
Go WY
DOI：
10.1038/nrclinonc.2017.148
发表时间：
2018-01
期刊：
Nature reviews. Clinical oncology
影响因子：
--
作者：
Neelapu SS;Tummala S;Kebriaei P;Wierda W;Gutierrez C;Locke FL;Komanduri KV;Lin Y;Jain N;Daver N;Westin J;Gulbis AM;Loghin ME;de Groot JF;Adkins S;Davis SE;Rezvani K;Hwu P;Shpall EJ
通讯作者：
Shpall EJ
影响因子：
28.5
作者：
Porter D;Frey N;Wood PA;Weng Y;Grupp SA
通讯作者：
Grupp SA
影响因子：
7.5
作者：
Dreger, Peter;Sureda, Anna;Hamadani, Mehdi
通讯作者：
Hamadani, Mehdi